This secondary analysis of the DAPHNe nonrandomized clinical trial showed excellent long-term outcomes with neoadjuvant THP in patients with early-stage ERBB2-positive breast cancer. Ultrasensitive circulating tumor DNA analyses demonstrated high baseline detection rates and near-universal clearance after abbreviated neoadjuvant therapy.
Study
|
Prospective, single-arm, investigator-initiated phase 2 nonrandomized clinical trial [DAPHNe, NCT03716180] |
| Stage II to III her2-positive breast cancer |
| Neoadjuvant paclitaxel, trastuzumab, and pertuzumab (THP) for 12 weeks (n=98)
|
Efficacy
|
ctDNA clearance in 49/51 pts |
| 5-yr EFS: 99% [97-100%] |
| 5-yr Recurrence-free interval: 98% [93-100%] |
| 5-yr distant RFI: 100% [100-100%] |
| 5-yr OS: 99% [97-100%]
|
Safety
|
Not reported
|
JAMA Oncol. Published online June 25, 2026
http://doi.org/10.1001/jamaoncol.2026.2023
Reviewed by Ulas D. Bayraktar, MD on Aug 13, 2026
